We have used homologous recombination in ES cells to engineer B cell-deficient mice that
are incapable of expressing endogenous immunoglobulin heavy and kappa light chain …

Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role …

Background and Aims: Antibodies to infliximab reduce serum infliximab with loss of clinical
benefit, but undetectable trough serum concentrations of infliximab may occur without …

Cyber-physical systems (CPSs) couple their cyber and physical parts to provide mission-
critical services, including automated pervasive health care, smart electricity grid, green …

Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology characterized by
symmetric, erosive synovitis and, in some cases, extraarticular involvement (1). Most …

Objective: To develop evidence based recommendations for the management of ankylosing
spondylitis (AS) as a combined effort of the 'ASsessment in AS'international working group …

Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat
rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient …

Background & Aims: We evaluated etanercept, a human soluble tumor necrosis factor
receptor: Fc fusion protein, for the treatment of active Crohn's disease. Methods: Forty-three …

Background Tumor necrosis factor (TNF) inhibitors are a mainstay in the treatment of
rheumatoid arthritis (RA), as well as in the management of spondyloarthritis (SpA) and …

Objective. To compare the benefits of initiating treatment with methotrexate (MTX) and
infliximab (anti–tumor necrosis factor [anti-TNF] monoclonal antibody) with those of MTX …